Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
DISEASE OF THE MONTH
You have accessRestricted Access

Anti-Glomerular Basement Membrane Disease

DAVID C. KLUTH and ANDREW J. REES
JASN November 1999, 10 (11) 2446-2453; DOI: https://doi.org/10.1681/ASN.V10112446
DAVID C. KLUTH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREW J. REES
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Anti-glomerular basement membrane disease (anti-GBM) is a rare but well-characterized cause of glomerulonephritis. It is defined by the presence of autoantibodies directed at specific antigenic targets within the glomerular and/or pulmonary basement membrane. These antibodies bind to the α3 chain of type IV collagen found in these specialized basement membranes. Its importance for the nephrologist lies in that it is a rare yet highly treatable cause of glomerulonephritis, but one in which delay in institution of the correct therapy can be fatal. This pattern of rapidly progressive glomerulonephritis and lung hemorrhage is often referred to as Goodpasture's syndrome and can be caused by a number of pathologies (Table 1). Ernest Goodpasture originally described autopsy findings in an 18 yr old with massive hemoptysis and acute renal failure during the influenza epidemic of 1918 (1). Thus, anti-GBM disease is a clearly defined cause of Goodpasture's syndrome; however, both pulmonary and renal disease can occur in isolation at least at presentation. A more extensive review of the condition has been published elsewhere (2).

View this table:
  • View inline
  • View popup
Table 1.

Cause of rapidly progressive glomerulonephritis/renal failure and lung hemorrhagea

Epidemiology

Anti-GBM disease has an estimated incidence of one case per 2 million per year in European Caucasoid populations (2). It is responsible for 1 to 5% of all types of glomerulonephritis (3) and is the cause in 10 to 20% of patients with crescentic glomerulonephritis (4,5). The disease occurs across all racial groups but is most common in European Caucasoids. All age groups are affected but the peak incidence is in the third decade in young men with a second peak in the sixth and seventh decades affecting men and women equally (2,6,7). Lung hemorrhage is more common in younger men, while isolated renal disease is more frequent in the elderly with near equal gender distribution.

Environmental factors are thought to play a role in triggering the disease. There are a number of case reports of clusters of patients with anti-GBM disease (8,9), which may implicate an infective agent; however, no clear viral association has been identified. Several anecdotal reports have linked anti-GBM disease to hydrocarbon exposure, with review of all cases suggesting a causal link (10,11). There have been case reports of anti-GBM disease following lithotripsy (12,13,14) and ureteric obstruction (15), suggesting that antigen released from a mechanically damaged kidney may initiate disease in susceptible individuals. Regardless of the role of environmental factors in initiating the autoimmune attack, the environment plays a critical role in determining whether anti-GBM antibodies cause lung injury. Pulmonary hemorrhage occurs in nearly all current cigarette smokers, while it is very rare in nonsmokers (16).

Disease Associations

A large number of diseases have been associated with Goodpasture's syndrome on the basis of individual cases; however, the most consistently reported associations are with membranous nephropathy (16,17,18,19,20) and anti-neutrophil cytoplasmic (ANCA)-associated vasculitis (17,18,19,20). Approximately 10% of patients with ANCA-positive vasculitis have anti-GBM antibodies, most of whom exhibit a perinuclear pattern of ANCA and antibodies against myeloperoxidase (21,22,23,24). Double-positive patients are notable because the disease behaves more like vasculitis than anti-GBM disease with a better response to therapy (23,25). It is reasonable to speculate that for both membranous and ANCA-positive vasculitis, damage to the kidney elicits an immune response against the GBM leading to the production of antibodies, which may or may not contribute to disease progression.

Genetic Susceptibility

Anti-GBM disease provides insight into the mechanisms of autoimmunity, in particular the role of human leukocyte antigens (HLA) in disease predisposition. HLA class II molecules, including DR, DP, and DQ, present antigen-derived peptides to T cells, thus initiating immune responses, including antibody production. Anti-GBM disease is associated with DR alleles (as opposed to DQ and DP) with strong positive associations with HLA-DR15 and HLA-DR4 alleles and negative associations with HLA DR-7 and HLA DR-1, both of which are dominantly protective (reviewed in reference 26). There are at least 18 DRβ alleles, and HLA DR15 has been split into the alleles DRB1*1501-1505. Analysis of these subsets in anti-GBM disease has shown that the disease is associated with DRB1*1501 and 1502, but the other DR15 alleles are too rare in Caucasian populations to assess. Exactly how these DR subgroups predispose to development of disease remains uncertain. Clearly, other factors are involved in disease initiation as DR 15 is relatively common in the general population, whereas anti-GBM disease is rare. Nevertheless, the dominant naturally processed Goodpasture antigen-derived peptides have been identified, and shown to bind to DR15 alleles with lower affinity than to the “protective” DR7 and DR1 alleles. This raises the question whether protective alleles “steal” the pathogenic peptides from DR15 (27,28).

Pathogenesis

The Goodpasture Antigen

The GBM is a specialized basement membrane separating the glomerular endothelial cells from visceral epithelial cells. It has contact with blood due to the presence of fenestrae in the endothelium, which allows antibodies direct access to the GBM for binding. Type IV collagens are found only in basement membranes and there are six types: α1 through α6. The major type IV collagens in most basement membranes are α1 and α2, whereas α3, α4, and α5 predominate in the GBM. Each chain of type IV collagen consists of a central long collagenous domain, a collagenous N-terminus (called the 7S domain), and the noncollagenous C-terminal (NC1 domain). Three α-chains self-assemble to form a monomer, and these monomers are linked at their NC1 domains by disulfide bridges producing a fixed hexamer. The monomers are also linked at the 7S domains, thus stabilizing this complex meshwork. The autoantibodies in anti-GBM disease are directed at the NC1 domain of the α3 chain of type IV collagen. Recent work has shown that the antibodies bind principally to the amino-terminal region of the NC1 domain (29,30,31). Although antibodies from patients may bind to other regions of the NC1 domain, only binding to the amino terminal region correlated with prognosis as assessed by dialysis dependency at 6 mo after antibody measurement (31). This antigen, as well as being located in the lung, is also found in a number of other specialized basement membranes, including Bruch's membrane in the eye and the retinal capillaries, cochlear, neuromuscular junction, and choroid plexus in the brain.

Anti-GBM Antibodies

Experiments by Lerner et al. (32) established that anti-GBM antibodies are pathogenic (33). They showed that antibodies eluted from kidneys of patients with Goodpasture's disease could bind to the GBM of squirrel monkeys when injected in vivo and elicit a pattern of disease similar to anti-GBM disease. Anti-GBM antibodies in kidney and blood have identical specificities (34), and further evidence for the pathogenicity of anti-GBM antibodies comes from the close correlation between disease activity and antibody level (35), and more recently by association between antibody binding to specific regions of the NC1 domain and renal prognosis (31). It should be emphasized, however, that the relationship between anti-GBM antibody level and glomerular injury is not straightforward: For example, intercurrent infection greatly increases the severity of glomerular injury independent of the anti-GBM antibody concentration. Cell-mediated mechanisms are important in generating the antibody with patients' T cells proliferating in response to exposure to Goodpasture antigen and are required to provide signals to enable B cell proliferation and antibody production. T cells have been isolated from patients with anti-GBM disease, which are reactive with autoantigens recognized by anti-GBM antibodies (36,37). In addition, there is evidence of T cells infiltrating the renal cortex in anti-GBM disease (38), and macrophages and neutrophils are a prominent feature within inflamed glomeruli, highlighting the importance of cell-mediated mechanisms in the effector phase of disease.

Clinical Features

General malaise, weight loss, fever, or arthralgia may be the initial features of anti-GBM disease in a way similar to but much less prominent than in systemic vasculitis. Symptoms relating to anemia may also occur even in the absence of significant hemoptysis. The principal clinical features relate to development of renal failure due to rapidly progressive glomerulonephritis or pulmonary hemorrhage.

Pulmonary Hemorrhage

Historically, hemoptysis has been the most common presenting feature, occurring in approximately 70% of reported cases and often preceding the onset of renal disease by months or years (3,39,40,41). The frequency of pulmonary hemorrhage is probably much less now because of the lower prevalence of cigarette smoking. The patients are frequently dyspneic with a cough; however, the degree of hemoptysis bears no correlation to the quantity of pulmonary hemorrhage, and the bleeding that occurs can lead to anemia. As mentioned earlier, pulmonary hemorrhage occurs almost exclusively in current smokers. In addition, it is known to be precipitated by intercurrent infections and fluid overload. It can be episodic and in many patients resolves spontaneously; in others, however, it can progress from minor hemoptysis to profound hemorrhage leading to respiratory failure in a matter of hours. Indeed, pulmonary hemorrhage is the primary cause of early death in anti-GBM disease, making prompt diagnosis imperative.

Clinical signs in lung hemorrhage are variable, often with signs on physical examination. Inspiratory crackles and occasionally bronchial breathing may be heard. Diagnosis may be made by noting a sudden fall in the hemoglobin in someone with hemoptysis, which is usually accompanied by radiologic changes on chest x-ray. The classical appearance of pulmonary hemorrhage includes alveolar-type shadowing with sparing of the upper lung fields. Unlike infection, shadowing tends not to be limited by fissures, and can resolve over 48 h. However, the picture is often complicated by coexistent fluid overload or infection. The KCO, a measure of the diffusion capability of the lung corrected for lung volume, is a sensitive indicator of lung hemorrhage. Because hemoglobin avidly binds carbon monoxide, the KCO is markedly elevated in lung hemorrhage (42,43). In addition to its diagnostic value, it also can provide a serial assessment to follow resolution of disease.

Despite the potential seriousness of lung hemorrhage, when patients recover there is virtually no residual pulmonary deficit or fibrosis. We and others have reported minor reductions in KCO at long-term follow-up (28).

Renal Manifestations in Anti-GBM Disease

Renal disease can occur in isolation or in association with pulmonary hemorrhage. In general, renal disease progresses rapidly once significant injury has occurred and rarely resolves spontaneously. The urine sediment shows microscopic hematuria with red cell cast formation as disease progresses, and in severe disease macroscopic hematuria may occur often with associated loin pain. Proteinuria is modest (<3 g/24 h), but can be heavier when the disease has a more subacute course. Progressive renal failure usually develops leading to oliguria, which is a poor prognostic sign, and under these conditions fluid overload, super-added infection, and lung hemorrhage with hypoxia all contribute to renal failure.

Diagnosis

Anti-GBM Antibodies

The diagnosis of Goodpasture's disease is dependent on the detection of anti-GBM antibodies either in the circulation or in kidney tissue. These antibodies are normally detected using an enzyme-linked immunosorbent assay method, although where doubt exists a Western blot in a specialized center will be required. The antibodies have not been reported to occur in the absence of disease, and false negatives are rare when appropriate checks are performed.

The antibodies can also be detected on renal biopsy specimens with characteristic linear staining for IgG and frequently C3 detected along the GBM; however, this pattern of staining has been reported in a number of other circumstances (Table 2) giving false positive results. The anti-GBM antibodies are nearly always IgG, however, there are case reports of both IgA and IgM antibodies causing disease (44).

View this table:
  • View inline
  • View popup
Table 2.

Causes of linear staining on direct immunofluorescence microscopy of kidney tissue

Renal Biopsy

A renal biopsy is essential in suspected anti-GBM disease, with renal involvement allowing diagnostic confirmation and assessing renal prognosis. The histologic pattern of disease starts with mesangial expansion and hypercellularity and progresses to focal and segmental glomerulonephritis with infiltration by leukocytes accompanied by segmental necrosis with prominent breaks in the GBM. Later, glomeruli develop extensive crescent formation composed of parietal epithelial cells and macrophages in association with destruction of the GBM. Of particular note (and in contrast to other forms of crescentic nephritis), the crescents are usually at the same stage of evolution—again emphasizing the explosive nature of the disease. Interstitial inflammation is usually present and may relate to the binding of antibody to basement membrane of distal convoluted tubules. As the disease progresses, the glomeruli show diffuse inflammation with segmental or total necrosis and extensive crescent formation, which eventually leads to scarring and the appearance of an end-stage kidney. Linear binding of IgG is universally detected by direct immunofluorescence. Linear C3 is found in 60 to 70% of kidney biopsies but does not influence the severity of the renal lesion.

Differential Diagnosis

The presentation with hemoptysis, lung hemorrhage, and rapidly progressive glomerulonephritis with anti-GBM antibodies makes Goodpasture's disease highly likely, with the main differential diagnosis being from vasculitis. There are a number of reports of patients with vasculitis having anti-GBM antibodies, and with the development of ANCA assays this most commonly occurs in association with myeloperoxidase antibodies (22). In general, they tend to have lower anti-GBM titers that are more readily suppressed by treatment (23,25,45) and can restore renal function even when presenting with severe renal failure unlike Goodpasture's disease. The other causes of pulmonary hemorrhage and renal disease are listed in Table 1 and can usually be distinguished by both clinical context and investigation.

Treatment

Without treatment, the prognosis for patients with anti-GBM disease is dismal. For example, 25 of 53 patients in Wilson and Dixon's series (3) died and only seven retained independent renal function. It appeared that neither steroids nor immunosuppressive drugs had an influence on the renal outcome. Certainly they have none on circulating anti-GBM antibody titers in the short term. The demonstration that anti-GBM antibodies were pathogenic provided a rationale for the current approach to treatment by therapeutic plasma exchange combined with immunosuppressive drugs. The regimen needs to be used intensively to be certain that circulating anti-GBM antibody concentrations will be reduced. Thus, daily whole volume exchanges have been advocated (Table 3). The effectiveness of this approach on improving renal function has been reported from a number of different centers (Table 4). Overall, renal function improves coincident with the introduction of plasma exchange in about 80% of patients with a serum creatinine <600 μmol/L, but in far fewer of those with higher levels or those who require dialysis. Improvement is usually evident within days of starting plasma exchange, which argues in favor of a direct effect. However, it should be emphasized that the regimen has never been properly assessed by a prospective randomized controlled trial because of the rarity and acuteness of the condition. The only reported randomized controlled trial was very small and used lower doses of both plasma exchange and cyclophosphamide than those used generally (46). Overall, plasma exchange is a relatively safe treatment and aids in a rapid reduction in anti-GBM antibodies before the longer-term immunosuppression reduces further antibody synthesis.

View this table:
  • View inline
  • View popup
Table 3.

Treatment of anti-GBM diseasea

View this table:
  • View inline
  • View popup
Table 4.

Results of studies assessing the effect of treatment on mortality and renal survivala

However, the poor outcome of those patients presenting with a creatinine >600 μmol/L may suggest that in the absence of pulmonary hemorrhage, the benefits of treatment are outweighed by the risks (47). There are a number of anecdotal reports of recovery in such patients (16,48,49,50) who usually have a short history with rapidly declining renal function and a renal biopsy revealing the recent onset of disease with possibly extensive crescent formation without evidence of scarring. Thus, even in the presence of severe renal failure, aggressive treatment may sometimes be justified in particular cases. Pulmonary hemorrhage is usually responsive to treatment with this regimen and may even respond to injection of methylprednisolone (51). Despite aggressive therapy, pulmonary hemorrhage is still the most common cause of death, especially in patients with infections.

Careful monitoring of the full blood count is essential. Cyclophosphamide should be stopped if the white cell count falls below 3.5 × 109/L, while sudden drops in the hemoglobin may reflect recurrent lung hemorrhage. The prednisolone is reduced at weekly intervals to 45 mg, 30 mg, 25 mg, then 20 mg with a slower reduction in dose after this point. Recommendations for monitoring progress after initial treatment are outlined in Table 5. If the disease is under control with no evidence of relapse, then normally all treatment can be stopped within 3 to 4 mo. The disease can relapse after initial symptoms have been controlled but before the antibody titer has been fully suppressed. This usually occurs with a rebound of anti-GBM antibody titers after stopping plasma exchange or more commonly due to superadded infection or fluid overload. Regular surveillance for infections and reducing potential sources of sepsis such as intravascular lines or urinary catheters is essential.

View this table:
  • View inline
  • View popup
Table 5.

Monitoring treatment of anti-GBM diseasea

Disease Recurrence

Recurrence of disease with antibody production has been reported but is quite rare. Recurrences may occur many years after the initial presentation with or without evidence of either renal or pulmonary disease (52,53,54,55). These episodes may occur spontaneously or be precipitated by infection or exposure to a toxic agent. Because the diagnosis in recurrent disease can be made more rapidly, outcome is usually better than with the original presentation. Renal transplantation is well known to initiate antibody production with or without renal disease (2). This should not preclude renal transplantation in patients with Goodpasture's disease but careful assessment is required. Our own practice is to delay engraftment for 6 mo after the antibody has become undetectable, and this approach is borne out by the experience of others (56). All patients will need careful monitoring for disease recurrence (presence of microscopic hematuria, rising anti-GBM titers, rising serum creatinine) after transplant; however, the incidence or recurrence is low, occurring in 1 to 12% of transplant recipients (56).

Anti-GBM Disease after Transplantation in Patients with Alport's Disease

Alport's syndrome is an inherited form of glomerulonephritis that usually progresses to end-stage renal failure. The primary abnormality is in the GBM, and it has been appreciated for many years that autoantibodies from patients with Goodpasture's disease did not bind to the GBM of these patients. In fact, the GBM in patients with Alport's lacks the α3, α4, and α5 chains. In the more common X-linked form of the disease, this is due to mutations in COL4A5, which encodes the α5 chain, whereas in the rare autosomal recessive form the defect is in the COL4A3 gene. Thus, there is absence of either α3, α4, or α5 chains in the GBM. It follows that after renal transplantation, patients with these diseases are at risk of developing anti-GBM antibodies directed at the normal α chains in the transplanted kidney. The transient appearance of low titers of these antibodies is not uncommon (57,58), but the risk of developing severe nephritis is small and the overall outcome for renal transplantation in patients with Alport's is good (59).

Nevertheless, there are at least 29 cases of anti-GBM disease after transplantation in Alport's syndrome (53). The onset occurs at a variable time after a first transplant and causes crescentic nephritis indistinguishable from Goodpasture's syndrome. The disease recurs in subsequent grafts, where it usually appears in the immediate post-graft period, coincident with the reappearance of anti-GBM antibodies and linear binding of IgG to the GBM. Treatment should be the same as for Goodpasture's syndrome, but the outlook is very poor with rapid development of severe crescentic nephritis (Figure 1).

             Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Progression of anti-glomerular basement membrane (anti-GBM) disease in an Alport's syndrome patient renal transplant. (A) Day 2 after renal transplant with normal histologic appearance in the glomerulus. (B) At day 7 after transplant, there is marked focal proliferation within the glomeruli, which progresses to destruction of the glomeruli and loss of architecture by day 12, as shown in Panel C.

An important practical point is that anti-GBM antibody titers may be low or even negative in conventional immunoassays that have been optimized to detect the α3(IV)NCI. This is because anti-GBM antibodies in this situation are directed primarily against the α5 chain, except in the rare patients with autosomal recessive disease (60). In some published cases, the target for alloantibodies appeared to be the α3 chain (61,62); however, reagents for specific detection of antibodies to the α5 chain of type IV collagen have only become available recently (60).

Conclusion

Anti-GBM disease is a rare cause of renal failure and lung hemorrhage, but a disease in which prompt diagnosis and initiation of correct therapy can produce a cure. It has also provided valuable insight into the mechanisms of human autoimmune disease, including an understanding of the presentation of autoantigens and the precise specificity of pathogenic antibodies. These approaches are being applied to other autoimmune diseases in an attempt to develop disease-specific therapies.

Footnotes

  • American Society of Nephrology

  • © 1999 American Society of Nephrology

References

  1. ↵
    Goodpasture EW: The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci158 : 863-870,1919
    OpenUrlCrossRefPubMed
  2. ↵
    Turner AN, Rees AJ: Antiglomerular basement membrane disease. In:Oxford Textbook of Nephrology , 2nd Ed., edited by Davison AM, Cameron JS, Grunfeld J-P, Kerr DNS, Ritz E, Winearls CG, Oxford University Press, 1998, pp 645-666
  3. ↵
    Wilson CB, Dixon FJ: Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int3 : 74-89,1973
    OpenUrlCrossRefPubMed
  4. ↵
    Couser WG: Rapidly progressive glomerulonephritis: Classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis11 : 449-464,1988
    OpenUrlCrossRefPubMed
  5. ↵
    Andrassy K, Kuster S, Waldherr R, Ritz E: Rapidly progressive glomerulonephritis: Analysis of prevalence and clinical course.Nephron 59:206 -212, 1991
    OpenUrlCrossRefPubMed
  6. ↵
    Segelmark M, Butkowski R, Wieslander J: Antigen restriction and IgG subclasses among anti-GBM autoantibodies. Nephrol Dial Transplant 5: 991-996,1990
    OpenUrlCrossRefPubMed
  7. ↵
    Merkel F, Pullig O, Marx M, Netzer KO, Weber M: Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: Report of 35 cases. Nephrol Dial Transplant9 : 372-376,1994
    OpenUrlPubMed
  8. ↵
    Simpson IJ, Doak PB, Williams LC, Blacklock HA, Hill RS, Teague CA, Herdson PB, Wilson CB: Plasma exchange in Goodpasture's syndrome. Am J Nephrol 2: 301-311,1982
    OpenUrlCrossRefPubMed
  9. ↵
    Perez GO, Bjornsson S, Ross AH, Aamato J, Rothfield N: A mini-epidemic of Goodpasture's syndrome clinical and immunological studies.Nephron 13:161 -173, 1974
    OpenUrlPubMed
  10. ↵
    Beirne GJ, Wagnild JP, Zimmerman SW, Macken PD, Burkholder PM: Idiopathic crescentic glomerulonephritis. Medicine56 : 349-381,1977
    OpenUrlPubMed
  11. ↵
    Bombassei GJ, Kaplan AA: The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). Am J Ind Med21 : 141-153,1992
    OpenUrlCrossRefPubMed
  12. ↵
    Guerin V, Rabian C, Noel LH, Droz D, Baron C, Lallemand F, Jungers: Anti-glomerular-basement-membrane disease after lithotripsy.Lancet 335:856 -857, 1990
    OpenUrlPubMed
  13. ↵
    Umekawa T, Kohri K, Iguchi M, Yoshioka K, Kurita T: Glomerular-basement-membrane antibody and extracorporeal shock wave lithotripsy. Lancet 341:556 , 1993
    OpenUrlPubMed
  14. ↵
    Xenocostas A, Jothy S, Collins B, Loertscher R, Levy M: Antiglomerular basement membrane glomerulonephritis after extracorporeal shock wave lithotripsy. Am J Kidney Dis 33:128 -132, 1999
    OpenUrlCrossRefPubMed
  15. ↵
    Weber MF, Andrassy K, Pullig O, Koderisch J, Netzer K: Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture's syndrome and in Wegener's granulomatosis. J Am Soc Nephrol 2:1227 -1234, 1992
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Donaghy M, Rees AJ: Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane.Lancet 2:1390 -1393, 1983
    OpenUrlPubMed
  17. ↵
    Klassen J, Elwood C, Grossberg AL, Milgrom F, Montes M, Sepulveda M, Andres GA: Evolution of membranous nephropathy into anti-glomerular-basement-membrane glomerulonephritis. N Engl J Med 290: 1340-1344,1974
    OpenUrlCrossRefPubMed
  18. ↵
    Moorthy AV, Zimmerman SW, Burkholder PM, Harrington AR: Association of crescentic glomerulonephritis with membranous glomerulonephropathy: A report of three cases. Clin Nephrol 6:319 -325, 1976
    OpenUrlPubMed
  19. ↵
    Richman AV, Rifkin SI, McAllister CJ: Rapidly progressive glomerulonephritis: Combined antiglomerular basement membrane antibody and immune complex pathogenesis. Hum Pathol12 : 597-604,1981
    OpenUrlCrossRefPubMed
  20. ↵
    Kurki P, Helve T, von Bonsdorff M, Tornroth T, Pettersson E, Riska H, Miettinen A: Transformation of membranous glomerulonephritis into crescentic glomerulonephritis with glomerular basement membrane antibodies: Serial determinations of anti-GBM before the transformation.Nephron 38:134 -137, 1984
    OpenUrlPubMed
  21. ↵
    Relman AS, Dvorak HF, Colvin RB: Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 46-1971. N Engl J Med 285:1187 -1196, 1971
    OpenUrlPubMed
  22. ↵
    Wahls TL, Bonsib SM, Schuster VL: Coexistent Wegener's granulomatosis and anti-glomerular basement membrane disease. Hum Pathol 18: 202-205,1987
    OpenUrlPubMed
  23. ↵
    Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis.Kidney Int 37:965 -970, 1990
    OpenUrlCrossRefPubMed
  24. ↵
    Weber MF, Andrassy K, Pullig O, Koderisch J, Netzer K: Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture's syndrome and in Wegener's granulomatosis. J Am Soc Nephrol 2:1227 -1234, 1992
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Bosch X, Mirapeix E, Font J, Borrellas X, Rodriguez R, Lopez-Soto A, Ingelmo M, Revert L: Prognostic implication of antineutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 36:107 -113, 1991
    OpenUrlPubMed
  26. ↵
    Phelps RG, Rees AJ: The HLA complex in Goodpasture's disease: A model for analysing genetic susceptibility to autoimmunity. Kidney Int 1999, in press
  27. ↵
    Phelps RG, Jones VL, Coughlan M, Turner AN, Rees AJ: Presentation of the Goodpasture autoantigen to CD4 T cells is influenced more by processing constraints than by HLA class II peptide binding preferences. J Biol Chem 273: 11440-11447,1998
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Phelps RG, Turner AN, Rees AJ: Direct identification of naturally processed autoantigen-derived peptides bound to HLA-DR15. J Biol Chem 271: 18549-18553,1996
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Kalluri R, Sun MJ, Hudson BG, Neilson EG: The Goodpasture autoantigen: Structural delineation of two immunologically privileged epitopes on alpha3(IV) chain of type IV collagen. J Biol Chem271 : 9062-9068,1996
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Ryan JJ, Mason PJ, Pusey CD, Turner N: Recombinant alpha-chains of type IV collagen demonstrate that the amino terminal of the Goodpasture autoantigen is crucial for antibody recognition. Clin Exp Immunol 113: 17-27,1998
    OpenUrlCrossRefPubMed
  31. ↵
    Hellmark T, Segelmark M, Unger C, Burkhardt H, Saus J, Wieslander J: Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int55 : 936-944,1999
    OpenUrlCrossRefPubMed
  32. ↵
    Lerner RA, Glassock RJ, Dixon FJ: The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis.J Exp Med 126:989 -1004, 1967
    OpenUrlAbstract
  33. ↵
    Lerner RA, Glassock RJ, Dixon FJ: The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis.J Am Soc Nephrol 10:1389 -1404, 1999
    OpenUrlPubMed
  34. ↵
    Saxena R, Bygren P, Butkowski R, Wieslander J: Specificity of kidney-bound antibodies in Goodpasture's syndrome. Clin Exp Immunol 78: 31-36,1989
    OpenUrlPubMed
  35. ↵
    Savage CO, Pusey CD, Bowman C, Rees AJ, Lockwood CM: Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4.Br Med J 292:301 -304, 1986
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Derry CJ, Ross CN, Lombardi G, Mason PD, Rees AJ, Lechler RI, Pusey CD: Analysis of T cell responses to the autoantigen in Goodpasture's disease.Clin Exp Immunol 100:262 -268, 1995
    OpenUrlPubMed
  37. ↵
    Merkel F, Kalluri R, Marx M, Enders U, Stevanovic S, Giegerich G, Neilson EG, Rammensee HG, Hudson BG, Weber M: Autoreactive T-cells in Goodpasture's syndrome recognize the N-terminal NC1 domain on alpha 3 type IV collagen. Kidney Int 49:1127 -1133, 1996
    OpenUrlCrossRefPubMed
  38. ↵
    Nolasco FE, Cameron JS, Hartley B, Coelho A, Hildreth G, Reuben R: Intraglomerular T cells and monocytes in nephritis: Study with monoclonal antibodies. Kidney Int 31:1160 -1166, 1987
    OpenUrlCrossRefPubMed
  39. ↵
    Herody M, Bobrie G, Gouarin C, Grunfeld JP, Noel LH: Anti-GBM disease: Predictive value of clinical, histological and serological data.Clin Nephrol 40:249 -255, 1993
    OpenUrlPubMed
  40. ↵
    Teague CA, Doak PB, Simpson IJ, Rainer SP, Herdson PB: Goodpasture's syndrome: An analysis of 29 cases. Kidney Int13 : 492-504,1978
    OpenUrlCrossRefPubMed
  41. ↵
    Briggs WA, Johnson JP, Teichman S, Yeager HC, Wilson CB: Antiglomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture's syndrome. Medicine 58:348 -361, 1979
    OpenUrlPubMed
  42. ↵
    Ewan PW, Jones HA, Rhodes CG, Hughes JM: Detection of intrapulmonary hemorrhage with carbon monoxide uptake: Application in Goodpasture's syndrome. N Engl J Med295 : 1391-1396,1976
    OpenUrlCrossRefPubMed
  43. ↵
    Bowley NB, Hughes JM, Steiner RE: The chest X-ray in pulmonary capillary haemorrhage: Correlation with carbon monoxide uptake. Clin Radiol 30: 413-417,1979
    OpenUrlCrossRefPubMed
  44. ↵
    Border WA, Baehler RW, Bhathena D, Glassock RJ: IgA antibasement membrane nephritis with pulmonary hemorrhage. Ann Intern Med91 : 21-25,1979
    OpenUrlCrossRefPubMed
  45. ↵
    Saxena R, Bygren P, Rasmussen N, Wieslander J: Circulating autoantibodies in patients with extracapillary glomerulonephritis.Nephrol Dial Transplant 6:389 -397, 1991
    OpenUrlCrossRefPubMed
  46. ↵
    Johnson JP, Moore JJ, Austin HA, Balow JE, Antonovych TT, Wilson CB: Therapy of anti-glomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors.Medicine 64:219 -227, 1985
    OpenUrlPubMed
  47. ↵
    Flores JC, Taube D, Savage CO, Cameron JS, Lockwood CM, Williams DG, Ogg CS: Clinical and immunological evolution of oligoanuric anti-GBM nephritis treated by haemodialysis. Lancet1 : 5-8,1986
    OpenUrlCrossRefPubMed
  48. ↵
    Walker RG, Scheinkestel C, Becker GJ, Owen JE, Dowling JP, Kincaid-Smith P: Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis/Goodpasture's syndrome. Q J Med54 : 75-89,1985
    OpenUrlPubMed
  49. ↵
    Cohen LH, Wilson CB, Freeman RM: Goodpasture syndrome: Recovery after severe renal insufficiency. Arch Intern Med136 : 835-837,1976
    OpenUrlCrossRefPubMed
  50. ↵
    Maxwell AP, Nelson WE, Hill CM: Reversal of renal failure in nephritis associated with antibody to glomerular basement membrane. Br Med J 297: 333-334,1988
    OpenUrlFREE Full Text
  51. ↵
    de Torrente A, Popovtzer MM, Guggenheim SJ, Schrier RW: Serious pulmonary hemorrhage, glomerulonephritis, and massive steroid therapy.Ann Intern Med 83:218 -219, 1975
    OpenUrlPubMed
  52. ↵
    Dahlberg PJ, Kurtz SB, Donadio JV, Holley KE, Velosa JA, Williams DE, Wilson CB: Recurrent Goodpasture's syndrome. Mayo Clin Proc53 : 533-537,1978
    OpenUrlPubMed
  53. ↵
    Mehler PS, Brunvand MW, Hutt MP, Anderson RJ: Chronic recurrent Goodpasture's syndrome. Am J Med 82:833 -835, 1987
    OpenUrlCrossRefPubMed
  54. ↵
    Hind CR, Bowman C, Winearls CG, Lockwood CM: Recurrence of circulating anti-glomerular basement membrane antibody three years after immunosuppressive treatment and plasma exchange. Clin Nephrol21 : 244-246,1984
    OpenUrlPubMed
  55. ↵
    Levy JB, Lachmann RH, Pusey CD: Recurrent Goodpasture's disease.Am J Kidney Dis 27:573 -578, 1996
    OpenUrlCrossRefPubMed
  56. ↵
    Netzer KO, Merkel F, Weber M: Goodpasture syndrome and end-stage renal failure—to transplant or not to transplant? Nephrol Dial Transplant 13:1346 -1348, 1998
    OpenUrlPubMed
  57. ↵
    Peten E, Pirson Y, Cosyns JP, Squifflet JP, Alexandre GP, Noel LH, Grunfeld JP, van Ypersele D, Querin S, Droz D: Outcome of thirty patients with Alport's syndrome after renal transplantation. Linear glomerular IgG fixation in renal allografts: Incidence and significance in Alport's syndrome.Transplantation 52:823 -826, 1991
    OpenUrlCrossRefPubMed
  58. ↵
    Querin S, Noel LH, Grunfeld JP, Droz D, Mahieu P, Berger J, Kreis H: Linear glomerular IgG fixation in renal allografts: Incidence and significance in Alport's syndrome. Clin Nephrol25 : 134-140,1986
    OpenUrlPubMed
  59. ↵
    Rigden SP, Mehls O, Jones EH, Valderrabano F: Report on management of renale failure in Europe, XXVI, 1995. The child-adult interface: A report on Alport's syndrome, 1975-1993. The ERA-EDTA Registry. Nephrol Dial Transplant 11[Suppl 7]:21-27, 1996
    OpenUrlPubMed
  60. ↵
    Brainwood D, Kashtan C, Gubler MC, Turner AN: Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation. Kidney Int 53:762 -766, 1998
    OpenUrlCrossRefPubMed
  61. ↵
    Kalluri R, Weber M, Netzer KO, Sun MJ, Neilson EG, Hudson BG: COL4A5 gene deletion and production of post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int45 : 721-726,1994
    OpenUrlCrossRefPubMed
  62. ↵
    Ding J, Zhou J, Tryggvason K, Kashtan CE: COL4A5 deletions in three patients with Alport syndrome and posttransplant anti-glomerular basement membrane nephritis. J Am Soc Nephrol 5:161 -168, 1994
    OpenUrlAbstract
  63. Benoit FL, Rulon DB, Theil GB, Doolan PD, Watten RH: Goodpasture's syndrome: A clinicopathologic entity. Am J Med58 : 424-444,1963
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 10 (11)
Journal of the American Society of Nephrology
Vol. 10, Issue 11
1 Nov 1999
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Anti-Glomerular Basement Membrane Disease
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anti-Glomerular Basement Membrane Disease
DAVID C. KLUTH, ANDREW J. REES
JASN Nov 1999, 10 (11) 2446-2453; DOI: 10.1681/ASN.V10112446

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Anti-Glomerular Basement Membrane Disease
DAVID C. KLUTH, ANDREW J. REES
JASN Nov 1999, 10 (11) 2446-2453; DOI: 10.1681/ASN.V10112446
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Epidemiology
    • Genetic Susceptibility
    • Pathogenesis
    • Clinical Features
    • Diagnosis
    • Differential Diagnosis
    • Treatment
    • Disease Recurrence
    • Anti-GBM Disease after Transplantation in Patients with Alport's Disease
    • Conclusion
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Exercise in the End-Stage Renal Disease Population
  • Nephronophthisis-Associated Ciliopathies
  • Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease
Show more DISEASE OF THE MONTH

Cited By...

  • Immunoadsorption in Anti-GBM Glomerulonephritis: Case Report in a Child and Literature Review
  • Atypical presentation of anti-GBM nephritis in a 90-year-old patient
  • Asymptomatic Autoantibodies Associate with Future Anti-glomerular Basement Membrane Disease
  • Pulmonary alveolar proteinosis
  • Experimental Autoimmune Anti-Glomerular Basement Membrane Glomerulonephritis: A Protective Role for IFN-{gamma}
  • Acute glomerulonephritis
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire